Abstract 151P
Background
Gastric cancer (GC) is the fourth leading cause of cancer-related deaths in Taiwan. Even with significant strides that have been made in GC early detection and management in Taiwan in recent years, patients with GC (including gastro-esophageal junction cancer, GEJC) that present with unresectable advanced metastatic disease (UAM) remain at risk for poor survival outcomes.
Methods
This was a retrospective ‘real world’ observational study using the linked Taiwan National Health Insurance Research Database, which contains health claims data on almost the entire Taiwan population, and the Taiwan National Cancer Registry. Patients having at least one hospital record with a primary ICD-9 or ICD-10 code of GC/GEJC were selected from Jan 1st, 2013 through Dec 31st, 2018. The first date of GC/GEJC diagnosis was defined as the index date. Patients were followed for a minimum ± 30 days from the index date and were stratified by staging, clinical presentation [i.e. resectable vs. unresectable advanced metastatic (UAM)]. Key characteristics such as demographics, clinical parameters, medication utilization, health care resource utilization, costs incurred, and survival were tracked for the overall population and both cohorts.
Results
A total of 3736 UAM GC patients were identified with a mean age of 68.0 (sd=15.2) years, with most patients being male (n=2248, 60.2%). The majority of UAM GC patients were Stage 4 (n=2270, 60.8%) and most patients were identified as having adenocarcinoma (n=2847, 76.2%). Nearly half the patients received 1st line (1L) therapy (n=1846, 49.4%) with the most common 1L therapies being Capecitabine + Oxaliplatin (n=604, 32.7% of 1L), S-1 (n=280, 15.2% of 1L) and Capecitabine monotherapy (n=209, 11.3% of 1L). Only 38.2% (n=1428) of patients survived 1 year with the annualized post-index GC-related costs being New Taiwan (NT) $ 396,590 (sd = NT$ 412,523).
Conclusions
The most common 1L chemotherapeutic treatments for UAM GC patients were Capecitabine + Oxaliplatin, S-1 and Capecitabine. In Taiwan, UAM GC patients appear to have poor survival and incur high GC-related costs, which suggests the need for new treatment options.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol-Myers Squibb Pharmaceuticals Corp.
Funding
Bristol-Myers Squibb Pharmaceuticals Corp.
Disclosure
C.J. Chang, Y. Tsai, H.S. Friedman, P. Navaratnam: Research grant/Funding (self): Bristol-Myers Squibb. J. Gricar, H. Xiao: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb.
Resources from the same session
286P - Improved diagnostic accuracy on MR imaging in post-surgical recurrent head and neck SCC lesions using decision tree classification system
Presenter: Ankush Jajodia
Session: e-Poster Display Session
287P - Establishment of nasopharyngeal carcinoma organoid culture system and preliminary exploration of drug sensitivity test in vitro
Presenter: Wang Wen
Session: e-Poster Display Session
288P - Application of volumetric modulated arc therapy (VMAT) in head and neck cancers: 5-year single institutional experience
Presenter: Hiep Doan
Session: e-Poster Display Session
289P - Radiotherapy in advanced nasopharyngeal carcinoma
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
292P - Shared decision-making at the cancer institute adult outpatient clinics of a tertiary hospital in the Philippines: A cross sectional study
Presenter: Marvin Jonne Mendoza
Session: e-Poster Display Session
293P - Prolonged release (PR) oxycodone/naloxone (OXN) for cancer pain (CP) & its impact on bowel function, safety & quality of life (QoL): Systematic review
Presenter: Sam Hjelmeland Ahmedzai
Session: e-Poster Display Session
294P - Interventional pain treatment in patients with pain syndrome in advanced tumours of small pelvis
Presenter: Yakhyo Ziyaev
Session: e-Poster Display Session
295P - Assessment of the impact of palliative care on the quality of life in advanced non-small cell lung cancer patients
Presenter: Sabin Katpattil
Session: e-Poster Display Session
296P - Outcomes of repeat transhepatic percutaneous biliary drainage in patients presenting with recurrent malignant biliary stricture
Presenter: Deevia Hanji
Session: e-Poster Display Session
297P - Factors affecting duration of admission in the palliative medicine ward of a tertiary cancer hospital: A pilot, investigator initiated, review of services
Presenter: Rahul D. Arora
Session: e-Poster Display Session